Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development

Rhea-AI Summary

Avant Technologies (OTCQB: AVAI) and Ainnova Tech are finalizing a prototype of a low-cost automated retinal camera that integrates with Ainnova's Vision AI platform. The camera will automatically capture and upload retinal images to the AI platform, which generates risk reports within seconds. The Vision AI software can detect multiple diseases including diabetic retinopathy, glaucoma, macular edema, cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. While Vision AI currently works with any fundus camera, this proprietary device aims to provide a cost-effective, user-friendly solution for market entry and capture. The development is being conducted through Ai-nova Acquisition Corp. (AAC), a joint venture between Avant and Ainnova, which holds global licensing rights for Ainnova's technology portfolio.

Positive

• Development of a low-cost automated retinal camera that could capture significant market share
• Seamless integration with Vision AI platform enabling quick patient referrals
• Comprehensive disease detection capabilities beyond just diabetic retinopathy
• Global licensing rights secured through joint venture for technology development and marketing

Negative

• Product still in prototype phase, not yet ready for full-scale development
• Currently trading on OTCQB market, indicating smaller market capitalization
• Potential competition from established fundus camera manufacturers

LAS VEGAS, June 4, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the Company is in the final stages of prototyping its proprietary automated retinal camera.  Ainnova's new device will offer users a low cost, easier to use camera that captures images automatically and then uploads those images to the Company's Vision AI software platform, which then produces a "risk report" in mere seconds.

Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said, "The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market.

"Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists.  Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach."

Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease.  The diseases that Vision AI can detect, include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration, and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova has integrated into the software like the detection of cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD).

Currently, Ainnova's Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera.

Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova's technology portfolio.  AAC owns the global licensing rights to develop, maintain, and market Ainnova's technology portfolio.

About Ainnova Tech, Inc.

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies, Inc. 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare.  With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

More information about Avant can be found at https://avanttechnologies.com 

You can also follow us on social media at:

https://twitter.com/AvantTechAI https://www.linkedin.com/company/avant-technologies-ai  

https://www.facebook.com/AvantTechAI 

https://www.youtube.com/@AvantTechAI 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements."  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.  Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Contact:
Avant Technologies, Inc. info@avanttechnologies.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-and-partner-ainnova-finalizing-automated-retinal-camera-prototype-ahead-of-full-scale-development-302473127.html

SOURCE Avant Technologies Inc.

FAQ

What diseases can Avant Technologies' (AVAI) Vision AI platform detect?

The Vision AI platform can detect diabetic retinopathy, glaucoma, macular edema, age-related macular degeneration, cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease.

How does Avant Technologies' (AVAI) automated retinal camera work?

The camera automatically captures retinal images and uploads them to the Vision AI software platform, which then produces a risk report within seconds.

What is the competitive advantage of Avant Technologies' (AVAI) new retinal camera?

The camera offers a significantly lower cost compared to existing market options and features seamless integration with the Vision AI platform for automated image processing and analysis.

Who owns the rights to Avant Technologies' (AVAI) retinal camera technology?

Ai-nova Acquisition Corp. (AAC), a joint venture between Avant and Ainnova, owns the global licensing rights to develop, maintain, and market the technology.

What is the current development status of Avant Technologies' (AVAI) retinal camera?

The camera is in the final stages of prototyping, preceding full-scale development.